About us

We make it our mission to enter into strategic partnerships for the acquisition, development and commercialisation of a robust portfolio of assets that are consistent with the vision of the Company, and to deliver value to our shareholders

Our model: Synergism optimised

The development of novel treatments is urgent for patients who suffer from potentially debilitating conditions and for whom there is no satisfactory standard of care. In order to address this need, our strategy is designed to optimise the time- and resource-efficient development of our pipeline candidates and for process excellence:

SynDermix identifies and acquires the rights to novel and commercially attractive assets from early-stage biopharmaceutical developers, academic research hubs or other companies following the discovery or pre-clinical phases of development

We then devote our resources to the state-of-the-art manufacturing of our pipeline candidates and to the robust demonstration of their innovation and clinical value — a set of activities that we outsource to our specialist partners, benefitting from their know-how and regulatory insights

For our products to reach patients, we out-license or divest the products to our corporate partners with the resources and expertise for commercialisation

Values

We are committed to values that we believe foster and sustain successful teamwork and partnerships, to innovation, and patient centricity:

We value integrity, dedication and fairness; we believe that success is achieved by people with a diverse range of talents and through mutual, synergistic efforts; we are driven by passion and professionalism

We view continued innovation as the answer to unmet and changing healthcare needs, and consider patient convenience as an equally important feature (together with efficacy and safety) in the therapies we select for development and commercialisation

Executive Team

We operate a lean structure, which leverages the complementary expertise of a seasoned executive team, distinguished service providers and key opinion leaders.

Konstantinos Efthymiopoulos, PharmD, PhD, MBA – Chief Executive Officer

Over 30 years’ international experience in big pharma, biotech and VC-backed companies (Farmitalia-Carlo Erba, Glaxo/GlaxoWelcome, Serono, Eurand, Funxional Therapeutics, Index Ventures) at increasingly senior levels that culminated in CSO, CEO and board positions. He is currently the Chairman of the Board of Synaffix BV and Biopôle SA, a Board Director of Metis Precision Medicine and the founder and Managing Director of PLUS Life Sciences Consulting Sàrl.

Jessica Kourniakti, DPhil – Chief Operating Officer

CEO and Chairwoman of Manage Mind AG, with over 6 years’ experience leading and managing strategic and communications projects at increasingly senior levels in the life science industry and academia. Past roles include: Director of Strategy and Marketing (2018–19) at SynDermix Management AG, Zurich; Teaching Fellow at the University of Oxford (2016–17); Convenor and Organiser of international conferences and colloquiums funded by the AHRC (2016), Onassis Public Benefit Foundation (2016), and the Oxford Research Centre in the Humanities (TORCH; 2015); and Marketing Manager at MastihaWorld Ltd., UK (2014-15). Obtained a DPhil from the University of Oxford (2018), MA from University College London (2011) and BA from the University of Bristol (2010).

Carlos Camozzi, MD, PhD, MBA – Clinical & Regulatory Development

Over 25 years’ international senior management experience in the biopharmaceutical industry (Roche, American Cyanamid, Mepha AG, Orphan Europe, UniQure, Orphazyme). Successfully led several regulatory achievements with both the EMA and the FDA. He is a permanent expert in the European Commission for Eureka and H2020 grant frames, and an expert in rare diseases and orphan drugs.

Rolf Küng, MBA – Finance & Controlling

A Swiss Certified Accountant and co-founder of the Institute For Innovative Trading (IFIT) in 1998. 17 years’ experience in auditing (Touche Ross, Deloitte Haskins & Sells, Grant Thornton and others). Has been a director and CEO of several companies within the IFIT Group with a focus on business projects in Europe and overseas, and is currently a consultant to ARIA Capital Management with offices in the UK, UAE, Greece and Switzerland.

Associates

Emilia Kouroussis, PhD — Associate Director

Over 6 years’ experience in medicinal chemistry and government-funded biochemical research in novel multi-step synthetic organic chemistry, proteomics, in vivo confocal microscopy and cell biology. Past positions include: science projects’ management and supervision in protein extraction & characterisation and cell culture, Caenorhabditis elegans , bacteria and yeast maintenance at the University of Bordeaux (2016-19); medicinal chemistry researcher in the synthesis of potential anti-breast cancer leads at University College London (2014-15); clinical chemistry and microbiology analyst at MEDLAB – Arnold Analytik, UAE (2012); and drug analyst at Specifar Pharmaceuticals SA, Greece (2009). Obtained a PhD from the University of Bordeaux (2019), with publications in Cell Metabolism  and Methods in Molecular Biology, and an MRes (2011) and BSc (2010) from Imperial College London.

Julian Heinrich, BSc — Administration & Data Management

Over 11 years’ experience in marketing and sales and information technology in the health insurance and finance industries (Munich RE and ERGO Insurance Group); holds a BSc degree in Media Information-Technology from the Hochschule der Medien, Stuttgart and is a qualified management assistant for marketing communications.

Board of Directors

Thomas Mehrling, MD, PhD – Chairman of the Board

Founder and Chairman of TNT Medical Corporation, Zurich, with more than 18 years’ experience in the pharmaceutical industry. Senior positions in different companies and across almost all functions in drug development and commercialisation, including: CEO of EDO GmbH, Basel; Medical Leader at Takeda European R&D Centre; Senior Vice President of Medical Affairs at Staticon International; and Head of Business Development (2000-4), European Director of Oncology (2004-11), and International Director of Oncology Strategy (2011-13) at Mundipharma International Ltd. During his tenure as Director of Oncology with Mundipharma, two major products were successfully launched in Europe: DepoCyte® and Levact® (Ribomustin®, Treanda®). A certified Pharmacist with a Ph.D. in pharmacology and a certified physician with an M.D. in haemato-oncology (both from Frankfurt University).

Konstantinos Efthymiopoulos, PharmD, PhD, MBA – Delegate of the Board

See Executive Team above.

Dieter Hemmer – Member of the Board

15 years’ senior executive experience at Nestlé as Head of the Strategic Business Unit (Nestlé Professional Food Services) and Chairman of the Pro Gastronomia Nestlé Foundation. Prior to Nestlé, he spent 22 years in a number of senior executive positions with Lufthansa, including Head of Global Inflight Service and Managing Director for Lufthansa Service (LSG) Asia. BSc in Economics from FHS Heidelberg and management education at INSEAD, London Business School and IMD.

Partners

IP, regulatory & corporate

Keltie

Intellectual property company, London

Danubia

Patent and law office, Budapest

ARIA Services

Financial and administrative services, Zurich

Manage Mind

Project management services for innovation industries, Zurich

Bihrer

Attorneys at law, Zurich

Balmer-Etienne

Tax consulting and audit services, Zurich

Bioscience Valuation

Biotechnology and pharmaceutical company economic, R&D and value assessors and consultants, Garmins

Manufacturing, Clinical & Non-Clinical

Fujifilm Diosynth

Biotechnologies manufacturer, Billingham

Creaholic

Professional inventors, Biel 

ISS

Clinical research organisation, Biel 

King’s College London

Institute of Pharmaceutical Science KCL, University of London